|
KMID : 0608520090150030075
|
|
Korean Journal of Oriental Medicine
2009 Volume.15 No. 3 p.75 ~ p.82
|
|
|
Anti-mutagenic and Anti-septic Effects of β-glucan from Aureobasidium pullulans SM-2001
|
|
Ku Sae-Kwang
|
|
|
Abstract
|
|
|
|
Anti-mutagenic and anti-septic effects of β-1,3/1,6-glucan from Aureobasidium pullulans SM-2001 were evaluated on the on the cyclophosphamide (CPA)-cecal ligation puncture (CLP) and CPA-treated mice. To induce immunosuppression and mutagenicity, 150 and 110 ㎎/㎏ of CPA were single intraperitoneally injected at 3 or 1 day before CLP or initial β-glucan administration. In CLP animals, the cecum was mobilized and ligated below the ileocecal valve, punctured through both surfaces twice with a 22-gauge needle. 125 ㎎/㎏ of β-glucan were dissolved in saline and subcutaneously or orally administered in a volume of 10 ml/㎏ (of body weight), 4 times, 12 hrs intervals from 6 hrs after CLP or 1 day after second dose of CPA. After treatment of β-glucan, the mortalities were observed in CPA-CLP model, and the appearance of a micronucleus is used as an index for genotoxic potential in CPA model. As results of CPA-CLP sepsis, all animals (9/9, 100%) in CPA-CLP control were dead within 2 days after CLP. In addition, increase of the number of bone marrow MNPCEs indicated mutagenicity were also observed by treatment of CPA. However, β-glucan treatment effectively inhibited the mortalities in CPA-CLP, and it also reduced the CPA treatment-related mutagenicity, respectively. These results indicated that β-glucan has effective anti-septic and anti-mutagenic effects and can be used as an agents for treating sepsis and mutagenicity related to high-dose chemotherapy or radiotherapy. However, further studies should be conducted to observe more detail action mechanisms of it’s anti-septic and anti-mutagenic effects.
|
|
|
KEYWORD
|
|
|
β-glucans, Aureobasidium pullulans SM-2001, Cecal ligation and puncture, Cyclophosphamide, Mice, Sepsis, Mutagenicity
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
|
|
|